Jefferies Financial Group Inc. acquired a new stake in shares of Avita Medical Inc. (NASDAQ:RCEL – Free Report) in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 37,500 shares of the company’s stock, valued at approximately $440,000.
A number of other large investors have also made changes to their positions in RCEL. BlackRock Inc. bought a new position in Avita Medical during the second quarter valued at about $2,333,000. NewEdge Advisors LLC lifted its position in shares of Avita Medical by 71.4% in the 2nd quarter. NewEdge Advisors LLC now owns 148,931 shares of the company’s stock worth $615,000 after acquiring an additional 62,046 shares during the period. Bank of America Corp DE lifted its position in shares of Avita Medical by 145.3% in the 1st quarter. Bank of America Corp DE now owns 62,128 shares of the company’s stock worth $230,000 after acquiring an additional 36,799 shares during the period. Ieq Capital LLC bought a new stake in shares of Avita Medical in the 2nd quarter worth approximately $134,000. Finally, Squarepoint Ops LLC acquired a new stake in shares of Avita Medical during the 2nd quarter worth approximately $95,000. Institutional investors and hedge funds own 27.66% of the company’s stock.
Avita Medical Price Performance
Shares of RCEL stock opened at $15.63 on Monday. The stock’s fifty day simple moving average is $13.40 and its 200 day simple moving average is $7.16. The firm has a market cap of $491.09 million, a price-to-earnings ratio of -13.25 and a beta of 2.03. Avita Medical Inc. has a one year low of $3.22 and a one year high of $18.43.
Avita Medical (NASDAQ:RCEL – Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The company reported ($0.20) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.04. The company had revenue of $26.11 million during the quarter, compared to the consensus estimate of $22.35 million. On average, research analysts anticipate that Avita Medical Inc. will post -0.94 earnings per share for the current year.
Analyst Ratings Changes
RCEL has been the topic of a number of research reports. Lake Street Capital boosted their price objective on Avita Medical from $12.00 to $20.00 and gave the company a “buy” rating in a research report on Friday, November 6th. Weiss Ratings restated a “sell (e+)” rating on shares of Avita Medical in a research note on Monday, September 21st. BTIG Research raised their target price on Avita Medical from $15.00 to $21.00 and gave the stock a “buy” rating in a research report on Friday, November 6th. Wall Street Zen upgraded shares of Avita Medical from a “hold” rating to a “buy” rating in a research note on Saturday. Finally, TD Cowen lifted their price target on shares of Avita Medical from $20.00 to $22.00 and gave the stock a “buy” rating in a research note on Thursday. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Avita Medical has an average rating of “Moderate Buy” and a consensus target price of $16.60.
Read Our Latest Stock Report on Avita Medical
Avita Medical Company Profile
AVITA Medical is a regenerative medicine company focused on treatments for skin restoration. Its flagship technology, the RECELL System, enables clinicians to use a small sample of a patient’s healthy skin to prepare a suspension of skin cells for application to wounds. The company’s RECELL products are used in the treatment of burns and certain other skin injuries, including full-thickness skin defects. The approach is intended to support wound coverage while reducing the amount of donor skin needed compared with conventional skin-grafting procedures.
Further Reading
- Five stocks we like better than Avita Medical
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding RCEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Avita Medical Inc. (NASDAQ:RCEL – Free Report).
Receive News & Ratings for Avita Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avita Medical and related companies with MarketBeat.com's FREE daily email newsletter.
